Exelixis EXEL
NASDAQ EXEL
$59.02 -0.11 (-0.19%)
As of: Sep 4, 2026 · 3:59 PM EDT

Exelixis (EXEL) Change in Receivables (2013 - 2026)

Exelixis (EXEL) posted quarterly Change in Receivables of $42.0 million for Q2 2026, up 160.75% year-over-year from $16.1 million in Q2 2025, and up 284.27% quarter-over-quarter from -$22.8 million in Q1 2026.

Analysis

Exelixis (EXEL) Change in Receivables (2013 - 2026) Analysis & Trends

Exelixis' Change in Receivables history runs 14 years deep, the most recent figure standing at $42.0 million for Q2 2026.

  • In Q2 2026, Change in Receivables rose 160.75% year-over-year to $42.0 million; the TTM figure through Apr 2026 stood at $47.3 million (up 15.68% YoY), while the FY2026 annual figure was $21.4 million, down 23.44% from the prior year.
  • Change in Receivables for Q2 2026 stood at $42.0 million, up from -$22.8 million in the prior quarter.
  • The five-year high for Change in Receivables was $156.0 million in Q2 2024, with the low at -$127.0 million in Q3 2024.
  • The 5-year median for Change in Receivables is $3.2 million (2024), against an average of $2.8 million.
  • The sharpest annual moves came in 2023 and 2024: Change in Receivables slumped 27370.73% in 2023, then soared 18223.93% in 2024.
  • Exelixis' Change in Receivables stood at $41000.0 in 2022, then plunged by 27370.73% to -$11.2 million in 2023, then slumped by 1036.08% to -$127.0 million in 2024, then surged by 113.67% to $17.4 million in 2025, then soared by 141.97% to $42.0 million in 2026.
  • Business Quant data shows EXEL's Change in Receivables at $42.0 million in Q2 2026, -$22.8 million in Q1 2026, and $17.4 million in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 140.20 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 838.50 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -53.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 117.58 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 31.60 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 37.16 Mn
10 Exelixis 14.81 Bn 13.97 Bn 608.03 Mn -6.73 Mn
Historic Data

Historic Data

Download Data
DateValue
Jul 3, 2026 -6.73 Mn
Apr 3, 2026 42.03 Mn
Jan 2, 2026 -22.81 Mn
Oct 3, 2025 17.37 Mn
Jul 4, 2025 10.72 Mn
Apr 4, 2025 16.12 Mn
Jan 3, 2025 -4.24 Mn
Sep 27, 2024 -127.03 Mn
Jun 28, 2024 156.05 Mn
Mar 29, 2024 3.17 Mn
Dec 29, 2023 -11.18 Mn
Sep 29, 2023 15.49 Mn
Jun 30, 2023 -861,000.00
Mar 31, 2023 19.18 Mn
Dec 30, 2022 41,000.00
Sep 30, 2022 -20.20 Mn
Jul 1, 2022 45.10 Mn
Apr 1, 2022 -91.79 Mn
Dec 31, 2021 102.20 Mn
Oct 1, 2021 7.81 Mn